Claims for Patent: 5,981,178

Summary for Patent: 5,981,178

Title:	Methods for screening for mutations at various positions in the introns and exons of the cystic fibrosis gene
Abstract:	The cystic fibrosis gene and its gene product are described for mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.
Inventor(s):	Tsui; Lap-Chee (Toronto, CA), Rommens; Johanna M. (Willowdale, CA), Kerem; Bat-sheva (Jerusalem, IL)
Assignee:	HSC Research Development Corporation (Toronto, CA)
Application Number:	08/469,461
Patent Claims:	1. A method of screening in vitro a subject to determine if said subject is a CF carrier or a CF patient comprising the steps of: providing a biological sample from the subject to be screened; and performing an in vitro nucleic acid assay for detecting in the biological sample the presence of a mutant CF gene, wherein said mutant gene encodes a mutant CFTR polypeptide product being defined by mutations selected from the group consisting of protein positions 85, 148, 178, 455, 493, 507, 542, 549, 551, 560, 563, 574, 1077, and 1092 of SEQ ID NO:2, and wherein an alteration at position 549 is either S549R or S549I. 2. A method for screening in vitro a subject to determine if said subject is a CF carrier or a CF patient comprising the steps of: providing a biological sample from the subject to be screened; and performing an in vitro nucleic acid assay for detecting in the biological sample the presence of a mutant CF gene having mutations at DNA sequence positions selected from the group consisting of 129, 556, 621+1, 711+1, 1717-1, and 3659 of SEQ ID NO:1. 3. The method of claim 1 or 2 wherein the biological sample includes at least part of the genome of the subject and the assay comprises a hybridization assay. 4. The method of claim 3 wherein the assay further comprises a labelled nucleotide probe comprising a DNA or RNA nucleotide sequence selected from the group consisting of: (a) DNA sequences comprising DNA sequences which encompass any one of said mutations of claims 1 or 2, said DNA sequence including at least 16 nucleotides; (b) DNA sequences comprising at least 16 nucleotides and encode a fragment of the selected amino acid sequence of claim 1 or 2; and (c) DNA sequences encoding an epitope characteristic of the mutant CFTR protein encoded by at least 18 sequential nucleotides in the selected sequence of claims 1 or 2. 5. The method of claim 4 wherein said DNA or RNA nucleotide sequence comprises AAA GAA AAT ATC TTT GGT GTT of SEQ ID NO:1, and its complement. 6. The method of claim 4, wherein the assay further includes at least one additional nucleotide probe comprising a DNA or RNA nucleotide sequence selected from the group consisting of: (a) DNA sequences comprising DNA sequences which encompass any one of said mutations of claims 1 or 2, said DNA sequence including at least 16 nucleotides; (b) DNA sequences comprising at least 16 nucleotides and encode a fragment of the selected amino acid sequence of claim 1 or 2; and (c) DNA sequence encoding an epitope characteristic of the mutant CFTR protein encoded by at least 18 sequential nucleotides in the selected sequence of claims 1 or 2. 7. The method of claim 6, wherein the assay further includes at least one additional nucleotide probe comprising a different DNA sequence fragment of the DNA sequence of SEQ ID NO:1 or its RNA homologue or a different DNA sequence fragment of human chromosome 7 and located to either side of the DNA sequence of SEQ ID NO:1. 8. The method of claim 1 or 2 wherein the subject is a human fetus in utero. 9. In a process for screening a potential CF carrier or patient to indicate the presence of an identified cystic fibrosis mutation in the CF gene, said process including the steps of: (a) isolating genomic DNA from said potential CF carrier or said potential patient; (b) hybridizing a DNA probe onto said isolated genomic DNA, said DNA probe spanning a mutation in said CF gene wherein said DNA probe is capable of detecting said mutation, said mutation being selected from the group of mutations at protein positions 85, 148, 178, 455, 493, 507, 542, 549, 551, 560, 563, 574, 1077 and 1092 of SEQ ID NO:2, and wherein an alteration at position 549 is either S549R or S549I. 10. The method of claim 9, wherein said method further includes after step (a) the step of amplifying a selected exon within said genomic DNA, said exon having a cDNA sequence of SEQ ID NO:1, using oligonucleotide primers in a polymerase chain reaction, the use of oligonucleotide primers being from intron portions of said genomic sequence near the 5' and 3' boundaries of a selected exon of SEQ ID NO:3. 11. In a process for screening a potential CF carrier or patient to indicate the presence of an identified cystic fibrosis mutation in the CF gene, said process including the steps of: (a) isolating genomic DNA from said potential CF carrier or said potential patient; (b) hybridizing a DNA probe onto said isolated genomic DNA, said DNA probe spanning a mutation in said CF gene where said DNA probe is capable of detecting said mutation, said mutation being selected from the group of mutations at DNA sequence positions 129, 556, 621+1, 711+1, 1717-1 and 3659 of SEQ ID NO:1. 12. A process for detecting cystic fibrosis carriers of a mutant CF gene wherein said process consists of determining differential mobility of heteroduplex PCR products in polyacrylamide gels as a result of deletions or alterations in the mutant CF gene at one or more of the protein positions 85, 148, 178, 455, 493, 507, 542, 549, 551, 560, 563, 574, 1077 and 1092 of SEQ ID NO:2. 13. A process for detecting cystic fibrosis carriers of a mutant CF gene wherein said process consists of determining differential mobility of heteroduplex PCR products in polyacrylamid gels as a result of deletions or alterations in the mutant CF gene at one or more of the DNA sequence positions 129, 556, 621+1, 711+1, 1717-1 and 3659 of SEQ ID NO:1. 14. A kit for assaying for the presence of a CF gene by hybridization comprising: (a) an oligonucleotide probe which specifically binds to a mutant CF gene; (b) reagent means for detecting the hybridization of the oligonucleotide probe to a mutant CF gene having a mutation at a protein position selected from the group consisting of protein positions 85, 148, 178, 455, 493, 507, 542, 549, 551, 560, 563, 574, 1077 and 1092 of SEQ ID NO:2, and wherein an alteration at position 549 is either S549R or S549I; and (c) the probe and reagent means each being present in amounts effective to perform the hybridization assay. 15. A kit for assaying for the presence of a CF gene by hybridization comprising: (a) an oligonucleotide probe which specifically binds to a mutant CF gene; (b) reagent means for detecting the hybridization of the oligonucleotide probe to a mutant CF gene having a mutation at a DNA sequence position selected from the group consisting of DNA sequence positions 129, 556, 621+1, 711+1, 1717-1 and 3659 of SEQ ID NO:1; and (c) the probe and reagent means each being present in amounts effective to perform the hybridization assay.

Details for Patent 5,981,178

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-11-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-11-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-11-09